|Day Low/High||267.67 / 274.54|
|52 Wk Low/High||223.25 / 374.99|
The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.
Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
And it is happening not a moment too soon.
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.
For the month of November RMPIA climbed 1.2% month over month.
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
Straying from these names could land you in quicksand as the 4th quarter begins.
Short-term price action may be volatile, but this name is still bullish long term.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
After Friday's surge another look at BIIB is warranted.
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
At midday tech, biotech ( dragging the group higher), homebuilders and energy are leading to the upside. There are really no large underperformers - though on a relative sense, autos, cap goods and semis are trailing. Banks fell initially, on the "d...
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
This biotech's weekly chart is very encouraging.
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
My longer-term price target is now $416.